EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes

Multiple myeloma (MM) remains a largely incurable hematologic cancer due to an inability to broadly target inevitable drug-resistant relapse. Epigenetic abnormalities are abundantly present in multiple myeloma and have increasingly demonstrated critical roles for tumor development and relapse to sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Harding, Taylor, Swanson, Jessica, Van Ness, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955152/
https://www.ncbi.nlm.nih.gov/pubmed/29774113
http://dx.doi.org/10.18632/oncotarget.25128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955152/
https://www.ncbi.nlm.nih.gov/pubmed/29774113
http://dx.doi.org/10.18632/oncotarget.25128

Ejemplares similares